AU: 1633 A

dkt. 0575/54202/JPW/JML

In re application

avid Stern, et al. PADEMARY

Serial No.:

08/997,464

Examiner: J. Kerr

Filed:

December 23, 1997

JUL 0 3 2000

Art Unit: 1633

For:

A METHOD FOR EVALUATING THE ABILITY OF A COMPOUND TO INHIBIT NEUROTOXICITY

June 30, 2000

HONORABLE ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

S I R: Transmitted herewith is an amendment to the above-identified $^{TECH}CEN_{TER}_{1600/2900}$

Small entity status of this application under 37 C.F.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.

a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.

No additional fee is required.

The filing fee is calculated as follows:

	NUMBER			HEST		NUMBER OF		R	ATE		FEE	
	AFTER AMEND- MENT			BER VIOUSLY D FOR		EXTRA CLAIMS PRESENTED		SMALL ENTITY	OTHER ENTITY	Y ENTI 00 = 0 00 = 0 0 0 = 0	SMALL ENTITY	OTHER ENTITY
Total Claims	11	, ,	*	33	=	*** O	x	\$ 9.00	\$ 18.00	=	0	
Indepen- dent Claims	1	-	**	4	=	*** O	×	\$ 39.00	\$ 78.00	=	. 0	
<pre>Aultiple Claims(s) For First</pre>	Presen		i	Yes	-	X No		\$ 130.00	\$260.00		0	
-		-						TOTAL FEE	ADDITIO	NA	L \$	0

*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, writ "20" in this space.

**If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than

3, write "3" in this space.

**If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

Applicant: David Stern, et al. U.S. Serial No.: 08/997,464
Filed: December 23, 2000

Amendment Transmittal Letter Page Tvo

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims as originally filed.

JUL 112007
TECHCENTER 1600/2900

v	check	in	the	 _,	125 00	

For a Three-Month Extension of Time

in the amount of \$____

Please charge Deposit Account No.

X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3125 . Three copies of this sheet are enclosed.

- X Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.
- X Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

John P. White

Reg. No. 28,678 Jane M. Love

Reg. No. 42,812

Panem Lone

John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorney for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



0575/54202/JPW

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David Stern et al.

Serial No. : 08/997,464 Examiner: J. Ken

Filing Date : December 23, 1997 Art Unit: 1633

For : A METHOD FOR EVALUATING THE ABILITY OF A

COMPOUND TO INHIBIT NEUROTOXICITY

1185 Avenue of the Americas New York, New York 10036

June 30, 2000

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

AMENDMENT IN REPLY TO JANUARY 3, 2000 OFFICE ACTION AND PETITION FOR A THREE-MONTH EXTENSION OF TIME

This Amendment is submitted in reply to the January 3, 2000 Office Action which was issued by the United States Patent and Trademark Office in connection with the above-identified application. A response to the January 3, 2000 Office Action was originally due on April 3, 2000. Applicants hereby request a three-month extension of time and a check including the FOUR HUNDRED AND THIRTY FIVE DOLLAR (\$435.00) fee is enclosed. Applicants have previously established small entity status. Therefore, a reply is now due July 3, 2000. Thus, this Amendment is being timely filed.

Please amend the subject application as follows:

In the claims:

Please amend claims 1, 2 and 11 as follows:

. (2x ,amended)

A method for evaluating the ability of a compound to inhibit neurotoxicity which

.c.

•